Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Aethlon Medical reported fiscal year results for the year ended March 31, 2026, with about $5.0 million cash. It said its Australian oncology Hemopurifier study completed Cohort 2 and entered the final Cohort 3, treating the first participant at Royal North Shore Hospital. Operating expenses fell 21.9% to about $7.3 million; operating loss was about $7.3 million.
Clinical execution and trial momentum (Cohort 3 dosing underway) plus IP expansion and lower operating expenses support a positive risk/reward setup for AEMD.
Aethlon entered the third and final dosing cohort in its Australian oncology study and reported the first Cohort 3 participant treated without device deficiencies.
Near-term upside bias as investors price progress toward final-cohort data; volatility likely given small-cap biotech trial uncertainty and cash burn context.
Background
Aethlon is a clinical-stage company developing the Hemopurifier for cancer and viral indications; this release covers FY results (ended Mar 31, 2026) and a corporate/clinical update.
Why it matters
The newest actionable items are (1) advancement into and first dosing of Cohort 3 in the Australian oncology study, (2) DSMB clearance of Cohort 2 with no safety concerns, (3) IP issuance for coronavirus/long-COVID applications, and (4) FY operating expense reduction plus a post-year-end ATM cash raise.
Market relevance
Company-specific clinical milestone (Cohort 3 dosing started) and IP expansion are likely to be the primary drivers for trader attention, with FY cash/expense and ATM raise informing financing risk.
Market effects
Reinforces investor appetite for extracorporeal/oncology platform progress and IP durability narratives in clinical-stage medtech/biotech.
Limited direct regional read-through; trial execution is in Australia but investors will treat it as global biotech progress.
Long-COVID/coronavirus IP and emerging pathogen preparedness references may broaden thematic interest beyond oncology.
Alternative perspectives
Cohort 3 is only the final dosing arm; without final trial readouts/statistical comparisons, the market may fade the news if data quality/endpoint signals are not yet available.
Cash is still modest (~$5.0M at FY-end) and the ATM raise is relatively small; dilution/financing risk can cap upside even with clinical momentum.
Key entities
- companyAethlon Medical, Inc.
Clinical-stage medical therapeutic company; reported FY2026 results and advanced Hemopurifier Cohort 3 dosing.
- siteRoyal North Shore Hospital
Australian investigative site where the first Cohort 3 participant was treated.
- labUniversity of Sydney (central lab)
Measured serial extracellular vesicle and T cell parameters for Cohort 2 participants.
- partnerStavro Medical
Developing a simplified blood treatment system; Aethlon is evaluating Hemopurifier compatibility.
- organizationWorld Health Organization (WHO) R&D Blueprint expert panel
Referenced as part of emerging pathogen preparedness efforts receiving the expanded access protocol/data.
